| TAIHO PHARMACEUTICAL CO., LTD. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120010165 | POTENTIATOR OF RADIATION THERAPY - To provide a radiation therapy potentiator, which, when employed in combination with cancer radiation therapy, can reduce radiation dose and can mitigate adverse effects. | 01-12-2012 |
| 20110319413 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE - This invention relates to a piperazine compound represented by Formula (I), | 12-29-2011 |
| 20110318764 | METHOD FOR DETECTING MUSCLE DEGENERATIVE DISEASES, AND METHOD FOR DETERMINING THERAPEUTIC EFFICACY ON THE DISEASES - Muscle degenerative diseases can be detected in the early stage and the therapeutic efficacy of a therapeutic agent and/or a therapy method for the diseases can be determined by measuring 11,15-dioxo-9α-hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid (referred to as “Tetranor-PGDM”, hereinbelow) in a sample isolated from a subject. | 12-29-2011 |
| 20110213179 | METHOD OF EVALUATING EVENNESS OF SUPLATAST TOSILATE CRYSTAL, EVEN CRYSTAL, AND PROCESS FOR PRODUCING THE SAME - Provided are a method for evaluating evenness of suplatast tosilate crystals; stable suplatast tosilate crystals exhibiting evenness in optical purity; and a method for producing the suplatast tosilate crystals. | 09-01-2011 |
| 20110172184 | ANTITUMOR AGENT CONTAINING 4 - [[3,5 - BIS (TRIMETHYLSILYL) BENZOYL] AMINO] BENZOIC ACID - Disclosed is a novel combination therapy of sorafenib having a remarkable antitumor effect. Specifically disclosed is an antitumor agent obtained by combining sorafenib or a salt thereof with 4-[[3,5-bis(trimethylsilyl)benzoyl]amino]benzoic acid or a salt thereof. | 07-14-2011 |
| 20110136810 | ANTITUMOR AGENT, KIT AND METHOD OF TREATING CANCER - Disclosed are an antitumor preparation comprising a combination of (1) a combination drug of tegafur/gimeracil/oteracil potassium, (2) at least one ingredient selected from the group consisting of folinic acid and pharmacologically acceptable salts thereof, and (3) cis-oxalate(1R,2R-diaminocyclohexane)platinum(II); a kit comprising a combination of pharmaceutical compositions for treating cancer in a mammal, comprising: (a) a combination drug of tegafur/gimeracil/oteracil potassium in a therapeutically effective amount; (b) a composition containing at least one ingredient selected from the group consisting of folinic acid and pharmacologically acceptable salts thereof in an amount effective for enhancing antitumor effects, and (c) a composition containing cis-oxalate(1R,2R-diaminocyclohexane)platinum(II) in an amount effective for enhancing antitumor effects; and a method for treating cancer. | 06-09-2011 |
| 20110118205 | ANTI-TUMOR AGENT COMPRISING CYTIDINE DERIVATIVE AND CARBOPLATIN - Provision of a novel combined therapy with ECyd, which therapy exhibits remarkable antitumor effect and gives less adverse effects. | 05-19-2011 |
| 20110091016 | POTENTIATOR FOR RADIATION THERAPY COMPRISING PYRIDINE DERIVATIVE AS ACTIVE INGREDIENT - The present invention relates to a radiotherapy enhancer that can reduce the radiation dose and adverse drug reactions when used in combination with a cancer radiotherapy. There is provided a radiotherapy enhancer comprising, as an active ingredient, a pyridine derivative represented by general formula (1): | 04-21-2011 |
| 20110082163 | NOVEL URACIL COMPOUND OR SALT THEREOF HAVING HUMAN DEOXYURIDINE TRIPHOSPHATASE INHIBITORY ACTIVITY - Provided is a uracil compound or a salt thereof, which has potent human dUTPase inhibitory activity and is useful as, for example, an antitumor drug. | 04-07-2011 |
| 20110034859 | IONTOPHORESIS PREPARATION FOR TREATING BREAST CANCER AND/OR MASTITIS - Provided is to enhance the therapeutic effect of an iontophoretic preparation for treatment of breast cancer or mastitis. | 02-10-2011 |
| 20110034439 | ACYLTHIOUREA COMPOUND OR SALT THEREOF, AND USE THEREOF - To provide an antitumor agent which exhibits excellent c-Met inhibitory effect and mitigates side effects by virtue of selectively affecting to tumor cells in which c-Met is specifically expressed. | 02-10-2011 |
| 20100330166 | AGENT FOR ENHANCING ANTI-TUMOR EFFECT COMPRISING OXALIPLATIN LIPOSOME PREPARATION, AND ANTI-TUMOR AGENT COMPRISING THE LIPOSOME PREPARATION - An object of the present invention is to further enhance the antitumor effect when oxaliplatin is administered in combination with a combination drug containing tegafur, gimeracil and oteracil potassium. According to the present invention, by using oxaliplatin encapsulated in a liposome preparation, combination therapy of oxaliplatin plus a combination drug containing tegafur, gimeracil and oteracil potassium, is revealed to show remarkably enhanced antitumor effect without increasing side effects. | 12-30-2010 |
| 20100266706 | ORAL PARTICULATE ANTITUMOR PREPARATION - An oral particulate antitumor preparation, which allows safe intake of antitumor agents, handling of which could be in many cases dangerous due to their high pharmacological activity, and has a stability equivalent to that of capsules or tablets, is provided. | 10-21-2010 |
| 20100240682 | PHOPHYLACTIC OR THERAPEUTIC AGENT FOR INFLAMATORY DISEASE COMPRISING THYMIDINE PHOSPHORYLASE INHIBITOR AS ACTIVE INGREDIENT - To provide an excellent agent for prevention or treatment of an inflammatory disease. | 09-23-2010 |
| 20100222372 | THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE COMPRISING URACIL DERIVATIVE AS ACTIVE INGREDIENT - To provide a therapeutic agent for inflammatory bowel disease. | 09-02-2010 |
| 20100216736 | 2'-CYANOPYRIMIDINE NUCLEOSIDE COMPOUND -
The present invention provides a pyrimidine nucleoside compound represented by the following formula (1):
| 08-26-2010 |
| 20100210591 | BIS(TRIMETHYLSILYL)PHENYL COMPOUND OR SALT THEREOF, AND USE THEREOF - The present invention provides a compound that exhibits an excellent antitumor effect and reduces side effects, such as skin disorders, of the existing retinoid by selectively activating on the nuclear receptor RARα, thereby possibly producing significant improvement of clinical profits. Specifically, the present invention provides a bis(trimethylsilyl)phenyl compound represented by Formula (I): | 08-19-2010 |
| 20100120709 | CYTIDINE DERIVATIVE-CONTAINING ANTITUMOR AGENT FOR CONTINUOUS INTRAVENOUS ADMINISTRATION - To provide a method for administering ECyd to a patient, which realizes a continuous therapy without expressing peripheral neurotoxicity caused by ECyd and which exhibits an excellent therapeutic effect with ensuring prolongation of the survival of the patient. | 05-13-2010 |
| 20100063162 | METHOD FOR PREDICTING EFFICACY OF RAR-ALPHA AGONIST - A method for predicting preventive and/or therapeutic effect of an RAR-α agonist on a malignant tumor, which comprises the steps of measuring an expression level of a class of p160 family molecule and an expression level of a class of SP110 family molecule in a sample collected from the malignant tumor of a patient, and when the class of the p160 family molecule is dominant in a balance between the expression level of the class of the p160 family molecule and the expression level of the class of the SP110 family molecule, determining that an RAR-α agonist is effective for therapeutic treatment of the malignant tumor of the patient. | 03-11-2010 |
| 20090318453 | POSTOPERATIVE ADJUVANT CHEMOTHERAPY FOR GASTRIC CANCER - The invention provides a method for treatment of gastric cancer, which method is a postoperative adjuvant chemotherapy for gastric cancer, comprising orally administering, to a patient with gastric cancer in stage II, IIIA, or IIIB in a classification of the stage of gastric cancer, a pharmaceutical composition containing Tegafur, Gimeracil, and Oteracil potassium at a molar ratio of 1:0.4:1, at a dose of 50 to 150 mg/day as Tegafur dose and according to an administration schedule including, from within 45 days after a surgical operation of gastric cancer, drug administration for 28 consecutive days, followed by a rest period of 7 to 14 consecutive days. | 12-24-2009 |
| 20090306008 | 3'-ETHYNYLCYTIDINE DERIVATIVE - To provide a compound which exhibits excellent anti-tumor activity and excellent oral absorption and which is a useful anti-tumor drug. | 12-10-2009 |
| 20090286755 | POTENTIATOR OF RADIATION THERAPY - To provide a radiation therapy potentiator, which, when employed in combination with cancer radiation therapy, can reduce radiation dose and can mitigate adverse effects. | 11-19-2009 |
| 20090281105 | RADIOTHERAPY ENHANCER - The present invention relates to a radiotherapy enhancer that can reduce the radiation dose and adverse drug reactions when used in combination with a cancer radiotherapy. A radiotherapy enhancer comprising (A) tegafur and (B) gimeracil. | 11-12-2009 |
| 20090281098 | BENZOIMIDAZOLE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHETASE - The present invention provides a benzimidazole compound represented by Formula (I) | 11-12-2009 |
| 20090281071 | THERAPEUTIC AGENT FOR HYPERTENSION - The present invention provides a novel hypertension therapeutic agent. | 11-12-2009 |
| 20090253922 | Process for Production of Steroid Compound - The present invention relates to a process for production of a steroid compound having a partial structure represented by Formula (2) by oxidizing a steroid compound having a partial structure represented by Formula (1), without the need of any special apparatus, in a safe and economical manner, with less adverse affect on environment, in a simple and high efficient manner. Specifically, the invention relates to a process for producing a steroid compound having a partial structure of ring A and ring B of the steroid skeleton represented by Formula (2): | 10-08-2009 |
| 20090209565 | THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE - The present invention relates to a therapeutic agent for inflammatory bowel disease comprising 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione or a pharmaceutically acceptable salt thereof as an active ingredient. | 08-20-2009 |
| 20090208982 | ASSAY METHOD FOR HUMAN OROTATE PHOSPHORIBOSYLTRANSFERASE PROTEIN - To establish an immunoassay method for human OPRT. | 08-20-2009 |
| 20090118222 | NOVEL PYRIMIDINE NUCLEOSIDE COMPOUND OR ITS SALT - A novel pyrimidine nucleoside compound represented by the following formula (1): | 05-07-2009 |
| 20090043101 | PROCESS FOR PRODUCTION OF 5-CHLORO-2,4-DIHYDROXYPYRIDINE - To provide an industrially advantageous process for producing 5-chloro-2,4-dihydroxypyridine, which is an inhibitor acting on a biodegradation enzyme that biodegrades an anti-malignant-tumor agent 5-fluorouracil. The process is carried out under mild conditions with a small number of steps and produces less industrial waste. | 02-12-2009 |
| 20090027947 | SEMICONDUCTOR MEMORY DEVICE AND DRIVING METHOD THEREOF - In a reading operation, an off time and a reading time of a holding control transistor is controlled by a replica circuit, so that a read margin is enlarged. Furthermore, a high power source potential and a low power source potential of an SRAM memory cell are switched in reading and writing operations of the memory cell and in a data holding state by a power source potential switching portion. As a result, a write margin is enlarged, and a leakage current is reduced. | 01-29-2009 |
| 20080275071 | Radiotherapy Enhancer - The present invention relates to a radiotherapy enhancer that can reduce the radiation dose and adverse drug reactions when used in combination with a cancer radiotherapy. A radiotherapy enhancer comprising (A) tegafur and (B) gimeracil. | 11-06-2008 |
| 20080275002 | Method for Treatment of Hepatic Cancer - A method for therapeutic treatment of hepatic cancer, which comprises the step of administering 10 to 30 mg per day of 4-[3,5-bis(trimethylsilyl)benzamido]-benzoic acid or a physiologically acceptable salt thereof to a patient with hepatic cancer. | 11-06-2008 |
